Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Ipriflavone]

K Kitatani1, H Morii

  • 1Osaka City University Medical School, Second Department of Internal Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|July 2, 1998
PubMed
Summary
This summary is machine-generated.

Ipriflavone, a non-hormonal osteoporosis treatment, reduces bone resorption and stimulates bone formation. Clinical studies show it maintains or increases bone mineral density (BMD) in postmenopausal women.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pathophysiological characteristics of non-alcoholic steatohepatitis-like changes in cholesterol-loaded type 2 diabetic rats.

Physiological research·2018
Same author

P38 delta MAPK promotes breast cancer progression and lung metastasis by enhancing cell proliferation and cell detachment.

Oncogene·2017
Same author

Long-term feeding of hydroalcoholic extract powder of Lepidium meyenii (maca) enhances the steroidogenic ability of Leydig cells to alleviate its decline with ageing in male rats.

Andrologia·2017
Same author

Feeding hydroalcoholic extract powder of Lepidium meyenii (maca) enhances testicular gene expression of 3β-hydroxysteroid dehydrogenase in rats.

Andrologia·2017
Same author

Correlation of Polar Lipid Composition with 16S rRNA Phylogeny in Methanogens. Further Analysis of Lipid Component Parts.

Bioscience, biotechnology, and biochemistry·2016
Same author

Transferrin facilitates the formation of DNA double-strand breaks via transferrin receptor 1: the possible involvement of transferrin in carcinogenesis of high-grade serous ovarian cancer.

Oncogene·2015
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Area of Science:

  • Pharmacology
  • Endocrinology
  • Bone Biology

Context:

  • Postmenopausal osteoporosis is a significant health concern.
  • Current treatments often have hormonal side effects.
  • Ipriflavone offers a non-hormonal therapeutic option.

Purpose:

  • To evaluate the efficacy of ipriflavone in preventing vertebral fractures.
  • To assess the effect of ipriflavone on bone mineral density (BMD).
  • To investigate ipriflavone's mechanism in bone remodeling.

Summary:

  • Ipriflavone, a synthetic isoflavone, inhibits osteoclast activity and bone resorption.
  • It also demonstrates potential in stimulating bone formation.
  • Clinical trials indicate ipriflavone can maintain or increase BMD.

Related Experiment Videos

Impact:

  • Ipriflavone represents a promising non-hormonal strategy for osteoporosis management.
  • Further research, including large multicenter studies like IMEFS, is validating its clinical utility.
  • This compound may reduce fracture risk and improve bone health in postmenopausal women.